Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

  1. Home
  2. PAAB Q&A
  3. Claims & Support/References for Claims
  4. 651 - If I have two clinical trials in slightly different patient populations, is it acceptable to present data from only one of the trials in an APS? Both populations fall under the same indication.
PAAB Notice
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.

651 - If I have two clinical trials in slightly different patient populations, is it acceptable to present data from only one of the trials in an APS? Both populations fall under the same indication.

Scheduled Pinned Locked Moved Claims & Support/References for Claims
1 Posts 1 Posters 191 Views
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • Jennifer CarrollJ Offline
    Jennifer CarrollJ Offline
    Jennifer Carroll
    wrote on last edited by
    #1

    The most relevant principles here appear to be that data presentations in advertising must be consistent with the TMA (s3.1), must not be overly-selective (s5.12), and must consider all relevant data (s. 5.5.i).
    Assuming both studies can be used in drug advertising (e.g. on-label, high-quality, etc.), you’d need to consider whether presenting data from only one study would be overly-selective (or misleading in some other way). This could potentially depend on many factors. For example, the degree of similarity between the populations, the extent to which the outcome in question differs between both studies, the degree of consistency with outcomes in the TMA, …etc.
    If an HCP who modifies her behaviour/attitude based on something learned from an APS about study A is likely to feel misled after later learning about study B, the APS likely requires inclusion of study B so as not to be overly-selective.

    1 Reply Last reply
    0
    Reply
    • Reply as topic
    Log in to reply
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes


    • Login

    • Don't have an account? Register

    • Login or register to search.
    • First post
      Last post
    0
    • Categories
    • Recent
    • Tags
    • Popular
    • Users
    • Groups